CA3239544A1 - Rabeximod compounds - Google Patents

Rabeximod compounds Download PDF

Info

Publication number
CA3239544A1
CA3239544A1 CA3239544A CA3239544A CA3239544A1 CA 3239544 A1 CA3239544 A1 CA 3239544A1 CA 3239544 A CA3239544 A CA 3239544A CA 3239544 A CA3239544 A CA 3239544A CA 3239544 A1 CA3239544 A1 CA 3239544A1
Authority
CA
Canada
Prior art keywords
compound
salt
rabeximod
rheumatoid arthritis
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239544A
Other languages
English (en)
French (fr)
Inventor
William Dalby Brown
Laurens Adrianus Hendricus Van Pinxteren
Rienk Elibert Steendam
Jonathan Knibbe
Malin Ingrid Berthold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyxone AB
Original Assignee
Cyxone AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyxone AB filed Critical Cyxone AB
Publication of CA3239544A1 publication Critical patent/CA3239544A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
CA3239544A 2021-12-09 2022-12-08 Rabeximod compounds Pending CA3239544A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21213418 2021-12-09
EP21213418.3 2021-12-09
PCT/EP2022/085060 WO2023104998A1 (en) 2021-12-09 2022-12-08 Rabeximod compounds

Publications (1)

Publication Number Publication Date
CA3239544A1 true CA3239544A1 (en) 2023-06-15

Family

ID=78827545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3239544A Pending CA3239544A1 (en) 2021-12-09 2022-12-08 Rabeximod compounds

Country Status (8)

Country Link
US (1) US11643415B1 (https=)
EP (1) EP4444720A1 (https=)
JP (1) JP2024546098A (https=)
KR (1) KR20240115849A (https=)
CN (1) CN118647618A (https=)
AU (1) AU2022407139A1 (https=)
CA (1) CA3239544A1 (https=)
WO (1) WO2023104998A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022880A (ko) * 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE527639C2 (sv) 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner
EA201500942A1 (ru) * 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형

Also Published As

Publication number Publication date
AU2022407139A1 (en) 2024-05-23
EP4444720A1 (en) 2024-10-16
CN118647618A (zh) 2024-09-13
KR20240115849A (ko) 2024-07-26
WO2023104998A1 (en) 2023-06-15
US11643415B1 (en) 2023-05-09
JP2024546098A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
RU2754856C2 (ru) Кристаллические формы соединения триазолопиримидина
US9452157B2 (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof
JP6535748B2 (ja) ベンズイミダゾール誘導体の新規結晶形及びその製造方法
US9884869B2 (en) Ibrutinib solid forms and production process therefor
EP3438099B1 (en) Vortioxetine pamoic acid salt and crystal form thereof
KR102593783B1 (ko) 결정성 화합물
JP2023553930A (ja) トレブルチニブの結晶形態、その製造方法、およびその使用
AU2017373239A1 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
WO2023076533A1 (en) Solid forms of mesembrine and therapeutic uses thereof
US11643415B1 (en) Rabeximod compounds
UA113302C2 (xx) Кристалічний поліморф 1-(3-трет-бутил-1-п-толіл-1h-піразол-5-іл)-3-(5-фтор-2-(1-(2-гідроксіетил)-1н-індазол-5-ілокси)бензил)сечовини гідрохлориду
CN105566314B (zh) 一种盐酸替扎尼定化合物
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
CN111194312A (zh) 依地普仑的新盐和固态形式
WO2019074908A1 (en) SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USE
JP2013529224A (ja) 結晶性エザチオスタット塩酸塩非溶媒和物
US8034813B2 (en) Polymorphs of brimonidine pamoate
CN112538124A (zh) 一种舒更葡糖钠晶型
AU2004232495B2 (en) 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo [2, 3d]pyrimidine hydrogen mesylate and its polymorphic forms
CA3067271A1 (en) Crystalline forms of ponatinib hydrochloride
AU2022234309B2 (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
US20260001883A1 (en) 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof
CA2768290A1 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for thepreparation thereof and pharmaceutical composition comprising the same for antimicrobial
Zaworotko et al. Nutraceutical co-crystal compositions

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241008

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241128

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251014

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251014